Optimizing the Use of Disease-Modifying Therapies Across the Spinal Muscular Atrophy Care Continuum: An Expert TheraTalk

Disease-modifying therapies (DMTs) have transformed the treatment of spinal muscular atrophy (SMA). However, optimizing their use in clinical practice, including across diverse ages and stages of disease progression, can be complex. How confident are you in integrating these therapies effectively into your practice? Tune in to this live expert TheraTalk, where a panel of SMA experts will discuss DMTs for SMA, focusing on their mechanisms of action, bioavailability, safety and efficacy data, and how these factors influence treatment decision-making.